Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: a longitudinal study by Barr, Helen L. et al.
Barr, Helen L. and Halliday, Nigel and Barrett, David A. 
and Williams, Paul and Forrester, Doug L. and 
Peckham, Daniel and Williams, Kate and Smyth, Alan R. 
and Honeybourne, David and Whitehouse, Joanna L. 
and Nash, Edward F. and Dewar, Jane and Clayton, 
Andrew and Knox, Alan J. and Cámara, Miguel and 
Fogarty, Andrew W. (2016) Diagnostic and prognostic 
significance of systemic alkyl quinolones for P. 
aeruginosa in cystic fibrosis: a longitudinal study. 
Journal of Cystic Fibrosis . ISSN 1873-5010 (In Press) 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/40106/1/1-s2.0-S1569199316306178-main.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the Creative Commons Attribution licence and may be 
reused according to the conditions of the licence.  For more details see: 
http://creativecommons.org/licenses/by/2.5/
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
www.elsevier.com/locate/jcf
Journal of Cystic Fibrosis xx (2016) xxx–xxx
JCF-01393; No of Pages 9Original Article
Diagnostic and prognostic signiﬁcance of systemic alkyl quinolones for
P. aeruginosa in cystic ﬁbrosis: A longitudinal study
Helen L. Barr a,⁎, Nigel Halliday b, David A. Barrett c, Paul Williams b, Douglas L. Forrester a,
Daniel Peckham d, Kate Williams d, Alan R. Smyth e, David Honeybourne f,
Joanna L. Whitehouse f, Edward F. Nash f, Jane Dewar g, Andrew Clayton g,
Alan J. Knox a, Miguel Cámara b, Andrew W. Fogarty h
a Division of Respiratory Medicine, University of Nottingham, City Hospital Campus, Nottingham, UK
b School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, UK
c Centre for Analytical Bioscience, School of Pharmacy, University of Nottingham, Nottingham, UK
d Leeds Adult Cystic Fibrosis Centre, St James's University Hospital, Leeds, UK
e Division of Child Health, Obstetrics and Gynaecology, University of Nottingham, UK
f West Midlands Adult CF Centre, Heart of England, NHS Foundation Trust, Birmingham, UK
g Wolfson Cystic Fibrosis Centre, Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK
h Division of Epidemiology and Public Health, University of Nottingham, Clinical Sciences Building, University of Nottingham, Nottingham, UK
Received 15 June 2016; revised 2 October 2016; accepted 6 October 2016Abstract
Background: Pulmonary P. aeruginosa infection is associated with poor outcomes in cystic ﬁbrosis (CF) and early diagnosis is challenging,
particularly in those who are unable to expectorate sputum. Speciﬁc P. aeruginosa 2-alkyl-4-quinolones are detectable in the sputum, plasma and
urine of adults with CF, suggesting that they have potential as biomarkers for P. aeruginosa infection.
Aim: To investigate systemic 2-alkyl-4-quinolones as potential biomarkers for pulmonary P. aeruginosa infection.
Methods: A multicentre observational study of 176 adults and 68 children with CF. Cross-sectionally, comparisons were made between current
P. aeruginosa infection using six 2-alkyl-4-quinolones detected in sputum, plasma and urine against hospital microbiological culture results. All
participants without P. aeruginosa infection at baseline were followed up for one year to determine if 2-alkyl-4-quinolones were early biomarkers
of pulmonary P. aeruginosa infection.
Results: Cross-sectional analysis: the most promising biomarker with the greatest diagnostic accuracy was 2-heptyl-4-hydroxyquinoline (HHQ). In
adults, areas under the ROC curves (95% conﬁdence intervals) for HHQ analyses were 0.82 (0.75–0.89) in sputum, 0.76 (0.69–0.82) in plasma and
0.82 (0.77–0.88) in urine. In children, the corresponding values for HHQ analyses were 0.88 (0.77–0.99) in plasma and 0.83 (0.68–0.97) in urine.
Longitudinal analysis: Ten adults and six children had a new positive respiratory culture for P. aeruginosa in follow-up. A positive plasma
HHQ test at baseline was signiﬁcantly associated with a new positive culture for P. aeruginosa in both adults and children in follow-up (odds ratio
(OR) = 6.67;-95% CI:-1.48–30.1;-p = 0.01 and OR = 70; 95% CI: 5–956;-p b 0.001 respectively).
Conclusions: AQs measured in sputum, plasma and urine may be used to diagnose current infection with P. aeruginosa in adults and children with
CF. These preliminary data show that plasma HHQ may have potential as an early biomarker of pulmonary P. aeruginosa. Further studies are
necessary to evaluate if HHQ could be used in clinical practice to aid early diagnosis of P. aeruginosa infection in the future.
© 2016 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.⁎ Corresponding author.
E-mail address: Helen.barr@nottingham.ac.uk (H.L. Barr).
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Chronic pulmonary infection with Pseudomonas aeruginosa
in patients with cystic fibrosis (CF) is an important risk factoris Society.
emic alkyl quinolones for P. aeruginosa in cystic ﬁbrosis: A longitudinal study, J
2 H.L. Barr et al. / Journal of Cystic Fibrosis xx (2016) xxx–xxxcontributing to recurrent hospital admissions [1] and increased
mortality [1]. The prevalence of P. aeruginosa infection in CF
increases with age, with approximately two thirds of adults either
intermittently or chronically colonised with this bacterium [2].
In the early stages of infection, P. aeruginosa may be eradicated
from the lungs with targeted antimicrobial therapy [3,4] which
positively affects the long term course of the disease [5].
There is a clinical need for better early markers for pulmonary
infection with P. aeruginosa to facilitate early intervention
with eradication therapy. In current clinical practice, the main
technique used to diagnose pulmonary P. aeruginosa infection is
conventional microbiological culture of respiratory specimens
[6]. Spontaneous sputum is quick and simple to culture and is
widely assumed to accurately diagnose common lower airway
pathogens [7]. However, early diagnosis of pulmonary
P. aeruginosa infection is more challenging in those who
are unable to expectorate sputum, such as young children and
adults with well maintained lung function. In these circumstances,
diagnostic options include sampling from the upper airways using
cough swabs, which have a low sensitivity and may miss lower
airways infection [8], or the use of more invasive techniques
such as induced sputum [9] or bronchoalveolar lavage [9]. More
recently, serological antibody tests against P. aeruginosa have
been used to aid diagnosis of infection [10–17]. Studies have
demonstrated that these antibodies can be used as markers of
chronic infection with P. aeruginosa [17], but their ability to
predict early infection with P. aeruginosa has so far been
relatively disappointing [11,14,17,18]. Finally, culture inde-
pendent techniques using molecular primer sequencing are
increasingly being used in a research setting to diagnose infection
in the lower airways [19], however these still require direct
airway samples and are subjected to false positives due to sample
contamination and the high sensitivity of these techniques.
In this study, we use novel LC–MS/MS methodology [20]
to directly measure specific quorum sensing signal molecules
(alkyl quinolones, AQs) in the systemic circulation of patients
with CF. These AQs regulate virulence factor production [21],
possess anti-staphylococcal properties [22], and have been
detected in infants with CF [23], suggesting that they may play
a role in the early stages of P. aeruginosa infection. The aim
of this study was to assess the diagnostic and prognostic
potential of plasma and urinary AQs as biomarkers for
pulmonary P. aeruginosa infection in patients with CF.
2. Methods
2.1. Participants
Patients were recruited from three adult CF centres
(Nottingham University hospitals NHS Trust, Heart of England
NHS Foundation Trust and Leeds Teaching Hospitals NHS
Trust) and one paediatric CF centre (Nottingham University
hospitals NHS Trust). Inclusion criteria were a diagnosis of CF and
exclusion criteria were any previous isolation of Burkholderia
cepacia complex in sputum. Control participants with no known
respiratory conditions and no history of P. aeruginosa infection
were invited to participate in the study. Informed written consentPlease cite this article as: Barr HL, et al, Diagnostic and prognostic signiﬁcance of syst
Cyst Fibros (2016), http://dx.doi.org/10.1016/j.jcf.2016.10.005was obtained from all participants or their legal representative and
the study was approved by the Nottingham Research Ethics
Committee 1 (09/H0407/1).2.2. Study design
Adults with CF were recruited at routine CF clinic appoint-
ments and were clinically stable at the study visit, having not
experienced a pulmonary exacerbation requiring intravenous
(IV) antibiotics in the previous 4 weeks. Spontaneous sputum,
8 ml blood and 25 ml urine samples were obtained. Pulmonary
function tests were performed according to standardised criteria
[24] and validated CFQ quality of life questionnaires were
completed [25].
Children with CF were recruited from paediatric CF clinics
and samples of plasma and urine were obtained at annual
assessment. Sputum collection was not requested from children.
A control population of healthy individuals was recruited by
poster advertisement and provided venous blood and urine
samples.2.3. Sputum, blood and urine processing
Spontaneous sputum samples were collected according to
standard guidelines [26,27]. Sputum plugs were harvested and
processed for quantitative QSSM analysis [28] and differential
cell counts [26,27]. Sputum plugs for quantitative microbiolog-
ical analysis were mixed with an equal volume of dithiothreitol
and diluted with 0.9%w/v saline and 100 μl of ×10−2 and ×10−4
solutions were plated on blood and pseudomonas isolation agar
(Difco; BD, Sparks, MD, USA). The plates were incubated at
37 °C and colony counts were performed daily between 24 and
72 h, until maximal growth was achieved. Venous blood samples
were centrifuged at 1000g for 15 min at 4 °C and plasma was
separated and snap frozen in liquid nitrogen. All biological
samples were stored on ice and frozen at −80 °C within 4 h.2.4. AQ analysis
Clinical samples for AQ analysis were analysed using
LC–MS/MS [20]. Measurement of AQ levels in clinical
samples was performed by comparison of extracts with
calibration standards. Further details of the sample preparation,
LC–MS/MS analysis and quantification can be found in the
online data supplement (S1). A total of six AQs were
studied: HHQ (2-heptyl-4-hydroxyquinoline), NHQ (2-nonyl-4-
hydroxyquinoline), C7-PQS (2-heptyl-3-hydroxy-4(1H)-quino-
lone), C9-PQS (2-nonyl-3-hydroxy-4(1H)-quinolone), HQNO
(2-heptyl-4-hydroxyquinoline-N-oxide) and NQNO (2-nonyl-4-
hydroxyquinoline-N-oxide) For 2-alkyl-4(1H)-quinolone (AQ)
and 2-alkyl-4-hydroxyquinoline N-oxide molecules, a previously
accepted nomenclature has been adopted [29]. A positive AQ test
was defined as a measured AQ concentration greater or equal to
the lower limit of quantification in the media of interest obtained
by LC–MS/MS (see online supplement, E1).emic alkyl quinolones for P. aeruginosa in cystic ﬁbrosis: A longitudinal study, J
Table 1
Clinical characteristics and P. aeruginosa status of participants with cystic
fibrosis.
Variable Adults Children
Hospital
Nottingham University
Hospitals NHS Trust
64 68
Heart of England NHS
Foundation Trust
76
Leeds teaching Hospitals
NHS Trust
36
Age in years:
median (range)
27.8 (17.7 to 65.2)
n = 176
9.6 (0.8 to 17.0)
n = 68
Gender, males (%) 104 (59) 31 (46)
FEV1 percent predicted:
mean (range)
65 (17 to 110)
n = 166
79 (41 to 121)
n = 35
Absolute FEV1 in L:
mean (range)
2.40 (0.71 to 4.78)
n = 165
1.70 (0.60 to 3.69)
n = 34
P. aeruginosa status at
baseline visit: n(%)
Never 20 (11) 19 (28)
Free 39 (22) 25 (37)
Intermittent 30 (17) 13 (19)
Chronic 86 (49)
n = 175 ⁎
11 (16)
n = 68
Maintenance treatment:
Azithromycin 105 (60) 35 (51)
Cycled nebulised Colomycin 83 (48) 11 (16)
Cycled nebulised Tobramycin 38 (22) 3 (4)
Number of patients with a
positive respiratory culture
for P. aeruginosa at baseline
in the hospital laboratory, n (%)
84 (48%) ^ 14 (21%)
n = number of participants with data available.
P. aeruginosa status of patients defined by the Leeds criteria [30].
⁎ 1 patient had no available respiratory samples in the previous 12 months
and P. aeruginosa status could therefore not be assessed.
^ Data missing for 2 patients.
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Current hospital microbiological culture results were used as
the reference standard for a diagnosis of P. aeruginosa and
were obtained from cough swabs, spontaneous sputum cultures
or bronchoalveolar lavage (BAL) using standard protocols [30].
Patients were categorised into four groups using the Leeds
criteria for P. aeruginosa [31]. The four groups were: ‘chronic’
(defined as ≥50% of samples positive for P. aeruginosa in the
last 12 months); ‘intermittent’ (defined as b50% of samples
positive for P. aeruginosa in the last 12 months); ‘free’ (defined
as previous P. aeruginosa infection but not isolated in the
last 12 months) and ‘never’ (defined as those who had not
previously isolated P. aeruginosa).
2.6. Statistical analysis
AQ concentrations in sputum, plasma and urine were
compared using scatter graphs and Spearman rank correlation
co-efficients. Each of the six AQs were compared to hospital
microbiological culture results in both adults and children with
CF. Sensitivity, specificity, positive predictive values and
negative predictive values were calculated for each AQ in
sputum, plasma and urine. Non-parametric receiver operator
characteristic (ROC) curves [30] and areas under the curves
(AUC) were used to compare each AQ to current hospital
culture results. Comparisons between P. aeruginosa groups
were assessed using Kruskal-Wallis testing. In the longitudinal
analysis, logistic regression was used to compare the presence
or absence of AQs in plasma and urine of adults and children
who had no evidence of P. aeruginosa infection in the previous
year with hospital respiratory culture results in the subsequent
12 months.
The association between AQ levels in plasma and clinical
variables of interest was explored using Spearman rank
correlation co-efficients or Mann Whitney U tests. These
explanatory variables were age, gender, forced expiratory volume
in 1 s (FEV1) percent predicted, quantitative load of P. aeruginosa
measured on pseudomonas isolation agar, sputum neutrophil
concentrations and the use of maintenance azithromycin and
nebulised antibiotics. All data were analysed using STATA 11
statistical software (Texas, USA).
3. Results
244 patients with CFwere recruited, 176 adults and 68 children.
Clinical characteristics, P. aeruginosa status of the participants
and hospital trust recruited from are shown in Table 1. In addition,
22 control participants were recruited from the general population
(11 males, median age = 31.7 years).
3.1. AQ concentrations in sputum, plasma and urine are
positively correlated between the biofluids
AQ concentrations were positively correlated between
sputum, plasma and urine with the strongest correlations between
sputum and plasma concentrations of HQNO (r = 0.84,Please cite this article as: Barr HL, et al, Diagnostic and prognostic signiﬁcance of syst
Cyst Fibros (2016), http://dx.doi.org/10.1016/j.jcf.2016.10.005p b 0.0001) and between sputum and urine levels of HHQ
(r = 0.79, p b 0.0001; online supplement E2).3.2. The use of AQs in sputum, plasma and urine to diagnose
current pulmonary P. aeruginosa infection
To evaluate the potential of AQs to diagnose current
P. aeruginosa infection, AQ results were compared to current
hospital respiratory culture results. In adults, the hospital
culture results were obtained from 136 spontaneous sputum
samples and 40 cough swabs. In children, 46 samples were
cough swabs, 20 samples were spontaneous sputum and 2
samples were obtained from BAL washings. Sensitivity and
specificity data for all six AQs are shown in the online
supplement (E3 and E4). Three patients had a new positive
respiratory culture for P. aeruginosa at the baseline visit,
having not isolated this bacterium in the preceding year, and
AQs were detectable in all 3 patients (online supplement E5).
Area under curve (AUC) results for each of the six AQs in
each biofluid are summarised in Table 2.emic alkyl quinolones for P. aeruginosa in cystic ﬁbrosis: A longitudinal study, J
Table 2
Area under receiver operating characteristic curves for six quorum sensing signalling molecules in biological samples from patients with cystic fibrosis compared to
current hospital respiratory culture results.
2-alkyl-4-quinolone tested Adults Children
Sputum
n = 88
Plasma n = 171 Urine n = 173 Plasma
n = 64
Urine
n = 55
AUC
(95% CI)
AUC
(95% CI)
AUC
(95% CI)
AUC
(95% CI)
AUC
(95% CI)
HHQ 0.82
(0.75–0.89)
0.76
(0.69–0.82)
0.82
(0.77–0.88)
0.88
(0.77–0.99)
0.83
(0.68–0.97)
HQNO 0.86
(0.79–0.93)
0.73
(0.67–0.78)
0.73
(0.67–0.79)
0.78
(0.64–0.92)
0.83
(0.70–0.96)
NHQ 0.82
(0.75–0.90)
0.58
(0.51–0.64)
0.63
(0.56–0.70)
0.65
(0.52–0.78)
0.69
(0.52–0.85)
NQNO 0.84
(0.76–0.91)
0.67
(0.62–0.73)
0.56
(0.52–0.59)
0.71
(0.57–0.84)
0.62
(0.49–0.74)
C7-PQS 0.71
(0.61–0.81)
0.66
(0.60–0.71)
0.66
(0.61–0.72)
0.71
(0.58–0.85)
0.72
(0.57–0.87)
C9-PQS 0.73
(0.62–0.85)
0.55
(0.51–0.58)
0.53
(0.49–0.57)
0.63
(0.51–0.75)
0.61
(0.47–0.75)
Prevalence of current PA infection
using respiratory culture results (%)
75 48 49 22 25
AUC = Area under Receiver Operating Characteristics curve.
PA = Pseudomonas aeruginosa.
HHQ = 2-heptyl-4-hydroxyquinoline.
HQNO = 2-heptyl-4-hydroxyquinoline-N-oxide.
NHQ = 2-nonyl-4-hydroxyquinoline.
NQNO = 2-nonyl-4-hydroxyquinoline-N-oxide.
C7-PQS = 2-heptyl-3-hydroxy-4(1H)-quinolone.
C9-PQS = 2-nonyl-3-hydroxy-4(1H)-quinolone.
n = number of samples available for analysis.
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(with the highest AUCs and therefore greatest diagnostic
accuracy) were HHQ (Fig. 1) and HQNO, and further analyses
focused on these two molecules. In adults, the sensitivity and
specificity of HHQ in plasma were 62% (95% CI: 51–73) and
80% (95% CI: 70–88) respectively and the corresponding
values in urine were 74% (95% CI: 63–83) and 84% (95% CI:
75–91) respectively (Table 3). In children, the presence of
HHQ in plasma had a sensitivity of 86% (95% CI: 57–98) and
specificity of 86% (95% CI: 73–94), and the corresponding
values in urine were 79% (95% CI: 49–95) and 71% (95%
CI: 55–84) respectively (Table 3). The prevalence of HHQ
and HQNO in each media is shown in the on line supplement
(E6).3.3. Relationship between plasma HHQ and HQNO with
P. aeruginosa infection status
Clinical samples from all patients with CF, stratified by
P. aeruginosa status were analysed, focusing on the two most
promising biomarkers, HHQ and HQNO. There were significant
differences in AQ concentrations between samples obtained from
adults with different categories of P. aeruginosa infection and
the control participants in all biofluids (Kruskal-Wallis test:
p ≤ 0.003 for both HHQ and HQNO in sputum, plasma and
urine; Fig. 2). Similar results were observed in plasma and urine
samples obtained from children with CF (Fig. 2, p b 0.02).Please cite this article as: Barr HL, et al, Diagnostic and prognostic signiﬁcance of syst
Cyst Fibros (2016), http://dx.doi.org/10.1016/j.jcf.2016.10.0053.4. Relationship between plasma HHQ and HQNO and
clinical status in adults (n = 176)
Overall, HHQ and HQNO levels in the plasma of adults
were negatively correlated with percent-predicted FEV1
(Spearman rank correlation coefficients, r = −0.19; p = 0.01
and r = −0.25; p = 0.001 respectively) and this association was
not significantly affected by adjustment for age. HHQ in
plasma was positively correlated with quantitative load of
P. aeruginosa in sputum (Spearman rank correlation
co-efficient: r = 0.28, p = 0.02) and negatively correlated
with the use of maintenance azithromycin, with higher values
in those who were receiving maintenance azithromycin therapy
compared to those who were not (Mann–Whitney U test: p =
0.004). No significant associations were observed between
plasma HQNO and P. aeruginosa load or plasma HQNO and
the use of azithromycin. There were no significant associations
between plasma HHQ and HQNO levels in adults and sputum
neutrophil concentration, age, gender, the use of maintenance
nebulised antibiotics or respiratory quality of life responses
(data not shown).
3.5. Longitudinal analysis: use of plasma and urinary AQs to
detect early P. aeruginosa infection
In the year following QSSM testing, a new positive
respiratory tract culture for P. aeruginosa was reported in andemic alkyl quinolones for P. aeruginosa in cystic ﬁbrosis: A longitudinal study, J
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Fig. 1. Receiver operator curves for 2-heptyl-4-hydroxyquinoline (HHQ) in sputum, plasma and urine in adults and children with cystic fibrosis compared to hospital
microbiological culture results.
5H.L. Barr et al. / Journal of Cystic Fibrosis xx (2016) xxx–xxx6 (14%) children and 10 (18%) adults who were categorised as
‘free’ or ‘never’ having isolated P. aeruginosa at baseline
(Table 4 and online supplement E7).
The presence of HHQ in plasma at baseline was significant-
ly associated with a new positive respiratory tract P. aeruginosa
culture in the following year in both adults and children with
CF (OR = 6.67; 95% CI 1.48 to 30.1; p = 0.01 and OR = 70;
95% CI: 5 to 956; p b 0.001 respectively; Table 4 and online
supplement E7).Please cite this article as: Barr HL, et al, Diagnostic and prognostic signiﬁcance of syst
Cyst Fibros (2016), http://dx.doi.org/10.1016/j.jcf.2016.10.005The presence of HHQ in urine or HQNO in plasma or urine
at baseline was not significantly associated with a new positive
P. aeruginosa respiratory tract culture in the following year in
children or adults (online supplement E7).
4. Discussion
This is the first study to test the diagnostic and prognostic
significance of systemic AQ quorum sensing signal moleculesemic alkyl quinolones for P. aeruginosa in cystic ﬁbrosis: A longitudinal study, J
Table 3
Evaluation of 2-heptyl-4-hydroxyquinoline (HHQ) for the diagnosis of P. aeruginosa compared to standard microbiological culture in adults and children.
Test (95% CI) Adults Children
Sputum
n = 88
Plasma
n = 171
Urine
n = 173
Plasma
n = 64
Urine
n = 55
Sensitivity, %
(95% CI)
71
(59–82)
62
(51–73)
74
(63–83)
86
(57–98)
79
(49–95)
Specificity, %
(95% CI)
86
(65–97)
80
(70–88)
84
(75–91)
86
(73–94)
71
(55–84)
PPV, %
(95% CI)
94
(84–99)
74
(62–84)
82
(71–90)
63
(38–84)
48
(27–69)
NPV, %
(95% CI)
50
(33–67)
70
(60–78)
77
(68–85)
96
(85–99)
91
(75–98)
Prevalence of PA using respiratory cultures results, % 75 48 49 22 25
PPV = positive predictive value.
NPV = negative predictive value.
PA = Pseudomonas aeruginosa.
A positive test was defined as an HHQ concentration greater or equal to the lower level of quantification in the sample type (see online supplement S1).
n = number of samples available for analysis.
6 H.L. Barr et al. / Journal of Cystic Fibrosis xx (2016) xxx–xxxas biomarkers for pulmonary P. aeruginosa in adults and
children with CF. Of the QSSMs measured, the diagnostic
accuracy of HHQ and HQNO were highest, suggesting these
molecules have potential as biomarkers of infection with
P. aeruginosa. The follow up data also permitted identification
of HHQ in plasma as a potential early biomarker of
P. aeruginosa. The consistency in these observations in both
adults and children with CF suggests that this finding may be
generalizable across all age groups. If externally validated,
these findings would be particularly important for young
children with CF, who stand to benefit the most from an early
diagnostic test for P. aeruginosa. This study also showed that
(1) higher concentrations of HHQ in plasma were associated
with lower percent-predicted FEV1 and higher bacterial load
and (2) systemic AQs concentrations were elevated in patients
with newly acquired P. aeruginosa infection, suggesting that
these molecules may be associated with an adverse prognosis.
These data also support our previous findings that systemic
levels of some AQs are elevated during pulmonary exacerba-
tions in adults with CF [33].
Strengths of the study include the large study population,
who were recruited from three specialist CF centres, with a
wide range of disease severities, which may be generalizable to
the broader UK CF population. The direct comparison of
sputum, plasma and urinary AQ levels in 87 adults demon-
strated that these were highly correlated, providing confidence
that the lower airways were the source of the AQs. We used
routine hospital culture results as our reference standard for
P. aeruginosa, thus comparing our test with current clinical
practice, and this was a necessary part of the study design.
However, this may underestimate the true value of the new
tests, as the diagnostic accuracy of both cough swabs and
sputum cultures is lower than BAL [6,32], which is considered
the ‘gold standard’ for defining lower airway microbiology.
There are several factors that require consideration when
interpreting these data. Firstly, multiple hypotheses were tested
and some of the associations observed may have occurred by
chance, although as most of the p values are small, this isPlease cite this article as: Barr HL, et al, Diagnostic and prognostic signiﬁcance of syst
Cyst Fibros (2016), http://dx.doi.org/10.1016/j.jcf.2016.10.005unlikely. Secondly, interpreting the clinical significance of low
levels of AQs is challenging. Low concentrations of several
AQs were detected in some adults who were classified as ‘free’
or ‘never’ having had P. aeruginosa infection and also in a
minority of the control population. This may represent
environmental exposure resulting in subclinical infection and
further investigation into these findings is warranted. Thirdly,
the numbers of patients who were negative for P. aeruginosa at
recruitment and subsequently developed infection was small.
This is reflected in the wide confidence intervals of the ORs,
which should be taken into account when interpreting these
data. Fourthly, we observed that patients with higher AQ
concentrations were more likely to be currently prescribed oral
azithromycin. There is currently no evidence that azithromycin
affects AQ production, although it inhibits the in vitro
production of some quorum sensing signal molecules from
the N-acyl-L-homoserine lactone class [34]. We suggest that
the use of azithromycin may be a confounding factor in this
study, as patients with chronic P. aeruginosa infection were
more likely to be prescribed azithromycin and chronic
P. aeruginosa infection was also associated with higher AQ
levels. In cross sectional analysis, the use of maintenance
nebulised antibiotics was not associated with differences in AQ
concentrations in plasma and urine. However, further studies
would be necessary to assess the impact of antibiotic therapy on
AQ levels at an individual level. Fifthly, the predictive values
for AQ tests should be interpreted in the context of disease
prevalence, as a higher disease prevalence is associated with
higher positive predictive values (PPVs) and lower negative
predictive values (NPVs) [35]. Thus, AQ testing in children be
used to confidently rule out infection (high NPV) but there is a
higher false positive rate (low PPV) compared to the adult
population, who had a higher prevalence of P. aeruginosa
infection.
Recently, serological antibody tests have been used to aid
the diagnosis of P. aeruginosa infection. Studies report varying
accuracies for serological tests, depending on the antigens
tested, the defined cut points, patient cohort and the testemic alkyl quinolones for P. aeruginosa in cystic ﬁbrosis: A longitudinal study, J
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Fig. 2. 2-heptyl-4-hydroxyquinoline (HHQ) concentration as a function of P. aeruginosa status in adults and children with cystic fibrosis and adult control
participants measured in the plasma and urine. Prevalence of HHQ in plasma above the lower limit of quantification using LC–MS/MS stratified by P. aeruginosa
status in adults: 25% (5/20) categorised as ‘never’, 18% (7/38) categorised as ‘free’, 27% (8/30) categorised as ‘intermittent’ and 60% (50/84) categorised as ‘chronic’
and 9% (2/22) in healthy controls. In children, the prevalence of HHQ in plasma, stratified by P. aeruginosa status was: 11% (2/18) in the ‘never’ category, 165 (4/25)
in ‘free’, 30% (3/10) in ‘intermittent’, 91% (10/11) in ‘chronic’ category. HHQ was detectable in the plasma of 3 controls and urine of 4 controls.
7H.L. Barr et al. / Journal of Cystic Fibrosis xx (2016) xxx–xxxstandard used [11,14,17,36]. Whilst direct comparisons be-
tween these studies are not possible, the diagnostic accuracy of
AQ tests in this study is broadly similar to serological test
results. However, there are some limitations of serological
antigen testing. Serological tests rely on detecting the host
immune response to infection and titres can be affected by
co-infection in the lungs [37] and by the concurrent use
of antibiotics [13,16,37,38] or oral steroids [39]. PotentialTable 4
Relationships between baseline plasma 2-heptyl-4-hydroxyquinoline (HHQ) and res
participants with CF who were classified as ‘free’ or ‘never’ having isolated P. aeru
P. aeruginosa culture ‘free’ or ‘never’
at baseline ^
Plasma HHQ result at
baseline visit #
Re
neg
Adults
n = 56 ⁎
HHQ negative 40
HHQ positive 6
Children
n = 42♦
HHQ negative 35
HHQ positive 1
n = number of samples available for analysis.
# A positive test was deﬁned as an HHQ concentration greater or equal to the low
^ P. aeruginosa status of patients deﬁned by the Leeds criteria [32].
⁎ 3 adults had no respiratory cultures reported by the hospital laboratory during 1
♦ 2 children did not provide plasma samples at the baseline visit.
Please cite this article as: Barr HL, et al, Diagnostic and prognostic signiﬁcance of syst
Cyst Fibros (2016), http://dx.doi.org/10.1016/j.jcf.2016.10.005advantages of AQ testing compared to serological testing
include the direct detection of bacterial products themselves
and the ability to detect these molecules in the urine, which
would allow non-invasive testing in children.
We acknowledge that this study represents an early step to
determine if AQs could aid clinical decision-making in CF in
future. One area for further investigation includes the testing
of AQs in control populations, in particular, the paediatricpiratory culture results for P. aeruginosa in the 12 month follow up period for
ginosa at baseline ^.
mained P. aeruginosa culture
ative during follow up
New positive culture for P. aeruginosa
during follow up
5
5
2
4
er level of quantiﬁcation (see online supplement S1).
-year follow up.
emic alkyl quinolones for P. aeruginosa in cystic ﬁbrosis: A longitudinal study, J
8 H.L. Barr et al. / Journal of Cystic Fibrosis xx (2016) xxx–xxxpopulation and also in patients with Burkholderia cepacia
complex. Another challenge is determining the clinical
significance of low levels of AQs. This is particularly
important, as low concentrations of AQs were detectable in
the plasma and urine of a minority of the control population.
Understanding the role of AQs in early infection with
P. aeruginosa in the CF population is another area that
deserves attention, as in vivo data are limited [40,41] and most
of our current knowledge comes from animal models or in vitro
studies [20]. Other areas that warrant investigation are the effects
of antibiotics, including eradication therapy, on systemic AQ
levels and understanding the metabolism and excretion of AQs.
Further steps include an external validation study, optimization
of cut points and comparisons of AQ tests to other tests for
P. aeruginosa used in clinical practice such as BAL, serological
tests and PCR. Finally, to bring this test to routine clinical
practice would also require development of a widely available
laboratory or point of care test, such as a biosensor for AQs [42],
which could be developed into a quick and cost effective bedside
test for P. aeruginosa.
In summary, these data suggest that AQs can be used to
determine current infection with P. aeruginosa. Limited data
also show that HHQ detected in the plasma may be an early
biomarker for pulmonary P. aeruginosa infection. If validated,
this finding would be particularly relevant in young children,
where diagnosis of pulmonary infection with P. aeruginosa is
challenging and early detection of P. aeruginosa is sought to
initiate timely eradication therapy. The high negative predictive
levels of plasma and urinary AQs in children suggest that these
tests may be useful in ruling out P. aeruginosa infection, thus
supporting robust infection control measures and risk stratifi-
cation of patients in CF clinics.Author statement
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